Back to top
more

TG Therapeutics (TGTX)

(Delayed Data from NSDQ)

$16.19 USD

16.19
4,803,433

-0.23 (-1.40%)

Updated May 3, 2024 04:00 PM ET

After-Market: $16.19 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (156 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for TGTX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

TG Therapeutics, Inc. [TGTX]

Reports for Purchase

Showing records 101 - 120 ( 275 total )

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 101

08/08/2018

Company Report

Pages: 6

TG Therapeutics Reports 2Q18 Results, MS Phase 3 Trials Reach Target Enrollment

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 102

08/07/2018

Daily Note

Pages: 3

TG Therapeutics Completes ULTIMATE I and II Target Enrollment Early

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 103

06/18/2018

Daily Note

Pages: 3

Umbralisib Data Updates at EHA

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 104

06/04/2018

Daily Note

Pages: 4

Umbralisib ASCO Update Incrementally Positive

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 105

06/04/2018

Company Report

Pages: 6

Updates From TG''s ASCO Analyst and Investor Meeting

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 106

05/08/2018

Company Report

Pages: 6

1Q18 Results: Phase 3 UNITY-CLL Data Expected This Summer

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 107

04/24/2018

Daily Note

Pages: 3

TG Reports Updated 24-Week MS Phase 2 Data at AAN 70th Annual Meeting; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 108

03/21/2018

Daily Note

Pages: 3

Dose Expansion Portion of Phase 1 Initiated for CK-301; First Registration Trial Expected in 1Q19

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 109

03/08/2018

Company Report

Pages: 6

4Q17 Results: Top-Line UNITY-CLL Data in 2Q18; Raising Price Target to $38

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 110

02/21/2018

Daily Note

Pages: 3

TG Announces Publication of Umbralisib Data in Lancet Oncology From a Phase 1 First-in-Human Study

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 111

02/02/2018

Daily Note

Pages: 3

TG Presents Six Month Results From Phase 2 Study in MS; Continued Safety and Efficacy Observed With Ublituximab

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 112

01/16/2018

Company Report

Pages: 7

Potential BLA Filing in 4Q18 Based on UNITY-CLL Trial; Management Meeting Highlights

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 113

01/08/2018

Daily Note

Pages: 3

TG Announces Global License Agreement With Jiangsu Hengrui Medicine for Development of Novel BTK Inhibitors

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 114

12/11/2017

Company Report

Pages: 8

Key Takeaways From ASH Investor - Analyst Event; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 115

11/27/2017

Daily Note

Pages: 3

TG Announces New Phase 2 Trial in Follicular Lymphoma for Umbralisib

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 116

11/14/2017

Company Report

Pages: 10

We are assuming coverage with a Buy rating

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 117

05/24/2017

Daily Note

Pages: 3

Corrected - Coverage Update - Healthcare

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 118

05/24/2017

Daily Note

Pages: 3

Coverage Update - Healthcare

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 119

05/24/2017

Company Report

Pages: 4

We are dropping coverage of TGTX shares to reallocate our research resources.

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 120

04/06/2017

Industry Report

Pages: 13

Healthcare - Cancer in Washington: 2017 AACR Highlights

Provider: Roth Capital Partners, Inc.

Analyst: BREIDENBACH M

Price: 50.00

Research Provided by a Third Party